Formoterol Fumarate Dihydrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 15 USDMF, 14 CEP/COS, 4 JDMF, 8 EU WC, 12 KDMF, 21 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

INTERMEDIATES

11 API Suppliers

11 API Suppliers

FINISHED DOSAGE FORMULATIONS

319 FDF Dossiers, 21 FDA Orange Book, 243 Europe, 8 Canada, 3 Australia, 11 South Africa, 33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INHALATION - 0.012MG/INH **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER, METERED;INHALATION - 0.4MG/INH;0.012MG/INH, AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH, AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH

RELATED EXCIPIENT COMPANIES

2 Nanjing Well Pharmaceutical, 5 Actylis, 2 BASF, 1 Clariant, 1 Finar, 3 Kerry, 1 Microlex e.U, 1 Nippon Fine Chemical, 1 Roquette

EXCIPIENTS BY APPLICATIONS

5 Parenteral, 3 Controlled & Modified Release, 3 Co-Processed Excipients, 3 Topical, 2 Granulation, 2 Direct Compression, 2 Emulsifying Agents, 2 Fillers, Diluents & Binders, 1 Film Formers & Plasticizers, 1 Lubricants & Glidants, 1 Surfactant & Foaming Agents, 1 Coating Systems & Additives, 1 Thickeners and Stabilizers, 1 Solubilizers, 1 Dry Powder Inhalation

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 64 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 193 Finished Drug Prices, 32 Annual Reports

MARKET PLACE

12 APIs

12 APIs

PATENTS & EXCLUSIVITIES

40 US Patents

40 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 8 Others

$ Xls

Filters

Also known as: Mls001401438, Chembl1895091, Hms2051p14, Hms2233m10, Ccg-101038, Nc00288

Molecular Formula

C₂₃H₃₀N₂O₉

Molecular Weight

478.5 g/mol

InChI Key

AXAGNMKWGBWLMO-GQMFVQBYSA-N

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1S)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate

2.1.2 InChI

InChI=1S/C19H24N2O4.C4H4O4.H2O/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);1H2/b;2-1+;/t13-,19+;;/m0../s1

2.1.3 InChI Key

AXAGNMKWGBWLMO-GQMFVQBYSA-N

2.1.4 Canonical SMILES

CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(=CC(=O)O)C(=O)O.O

2.1.5 Isomeric SMILES

C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\C(=O)O.O

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. Mls001401438

2. Chembl1895091

3. Hms2051p14

4. Hms2233m10

5. Ccg-101038

6. Nc00288

7. Smr000471620

2.3 Create Date

2007-12-08

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₃₀N₂O₉
Molecular Weight	478.5 g/mol
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	10
Exact Mass	478.19513054 g/mol
Monoisotopic Mass	478.19513054 g/mol
Topological Polar Surface Area	166 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	507
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

Formoterol Fumarate Dihydrate

Formoterol Fumarate Dihydrate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers

15 USDMF

14 CEP/COS

4 JDMF

8 EU WC

12 KDMF

21 NDC API

26 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

INTERMEDIATES

11 API Suppliers

FINISHED DOSAGE FORMULATIONS

319 FDF Dossiers

21 FDA Orange Book

243 Europe

8 Canada

3 Australia

11 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INHALATION - 0.012MG/INH **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER, METERED;INHALATION - 0.4MG/INH;0.012MG/INH

AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH

AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH

RELATED EXCIPIENT COMPANIES

2 Nanjing Well Pharmaceutical

5 Actylis

2 BASF

1 Clariant

1 Finar

3 Kerry

1 Microlex e.U

1 Nippon Fine Chemical

1 Roquette

EXCIPIENTS BY APPLICATIONS

5 Parenteral

3 Controlled & Modified Release

3 Co-Processed Excipients

3 Topical

2 Granulation

2 Direct Compression

2 Emulsifying Agents

2 Fillers, Diluents & Binders

1 Film Formers & Plasticizers

1 Lubricants & Glidants

1 Surfactant & Foaming Agents

1 Coating Systems & Additives

1 Thickeners and Stabilizers

1 Solubilizers

1 Dry Powder Inhalation

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow

64 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

193 Finished Drug Prices

32 Annual Reports

MARKET PLACE

12 APIs

PATENTS & EXCLUSIVITIES

40 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 USP

8 Others

Filters

POWDER;INHALATION - 0.012MG/INH Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons